Christian & Timbers is pleased to announce that Telix Pharmaceuticals has appointed William (Bill) Jellison as a Non-Executive Director, effective May 11, 2026. The appointment adds significant financial oversight and public company governance experience to the Telix board.
Jellison is a corporate finance leader with more than 30 years of experience across large, regulated operating environments. He served most recently as Vice President and CFO of Stryker Corporation (NYSE: SYK), one of the world's leading medical technology companies, where he oversaw international finance, SEC reporting, mergers and acquisitions, and capital allocation. His tenure at Stryker reflects the kind of financial discipline and strategic rigor that public company boards require at scale.
His current board directorships include serving as Audit Chair of Solenis and as a board member of Medtronic plc (NYSE: MDT), Anika Therapeutics, Inc. (NASDAQ: ANIK), Avient Corporation (NYSE: AVNT), and Young Innovations, Inc. He previously served as a director of Masimo Corporation (NASDAQ: MASI). Jellison holds a B.A. in Business Administration from Hope College.
Telix Pharmaceuticals is a commercial-stage biopharmaceutical company at the forefront of radiopharmaceuticals for targeted cancer diagnostics and therapy. The company closed FY 2025 with US$804 million in revenue, is targeting US$950 to $970 million in 2026, and has three pivotal-stage trials underway across prostate, kidney, and brain cancer.
As Telix continues its evolution as a dual-listed, global biopharmaceutical company, Jellison's experience in capital allocation, financial governance, and audit committee leadership positions the board to manage that growth with rigor and confidence. Congratulations to Mr. Jellison and the Telix leadership team on this appointment.